Cargando…
Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms’ Tumor 1 in Patients with Advanced Colorectal Cancer
Despite significant recent advances in the development of immune checkpoint inhibitors, the treatment of advanced colorectal cancer involving metastasis to distant organs remains challenging. We conducted a phase I study to investigate the safety and immunogenicity of Wilms’ tumor (WT1) class I/II p...
Autores principales: | Shimodaira, Shigetaka, Sano, Kenji, Hirabayashi, Koichi, Koya, Terutsugu, Higuchi, Yumiko, Mizuno, Yumiko, Yamaoka, Naoko, Yuzawa, Miki, Kobayashi, Takashi, Ito, Kenichi, Koizumi, Tomonobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693229/ https://www.ncbi.nlm.nih.gov/pubmed/26690485 http://dx.doi.org/10.3390/vaccines3041004 |
Ejemplares similares
-
Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms’ Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination
por: Higuchi, Yumiko, et al.
Publicado: (2015) -
Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity
por: Koya, Terutsugu, et al.
Publicado: (2017) -
In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination
por: Shimodaira, Shigetaka, et al.
Publicado: (2019) -
Dendritic Cells Pre-Pulsed with Wilms’ Tumor 1 in Optimized Culture for Cancer Vaccination
por: Koya, Terutsugu, et al.
Publicado: (2020) -
Different In Vitro-Generated MUTZ-3-Derived Dendritic Cell Types Secrete Dexosomes with Distinct Phenotypes and Antigen Presentation Potencies
por: Sakamoto, Takuya, et al.
Publicado: (2022)